Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Onyx Therapeutics Inc. operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio is engaged in 1 pending office action, reflecting a precise and limited scope of active prosecution. This matter is being reviewed by 1 distinct examiner, which centralizes the company's current interactions with the patent office. The portfolio's activity is also restricted to 1 distinct art unit, indicating that the company's technological focus is currently concentrated in a single specialized area of pharmaceutical technology.
The busiest examiner for Onyx Therapeutics Inc. is MYERS, CARLA J, who is handling the 1 pending office action. As the sole examiner with an active case, MYERS, CARLA J is the primary gatekeeper for the company's current intellectual property goals. For a practitioner, having 1 busiest examiner pending case allows for a deep focus on a single set of examiner concerns rather than managing multiple conflicting requirements. The limitation to 1 distinct art unit further suggests that the prosecution will follow the specific procedural norms of that unit, providing a predictable environment for the company's legal strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MYERS, CARLA J | 1 | 49.5% | +46.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17903700 | IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE | MYERS, CARLA J | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17903700 | IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE | MYERS, CARLA J | 1682 | §103Other | Final Rejection | — | Pending | Sep 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOnyx Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Carla J Myers has the most, with 1 of Onyx Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.